Company registration number 13681455 (England and Wales)
RUBY PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
PAGES FOR FILING WITH REGISTRAR
RUBY PHARMACY LIMITED
CONTENTS
Page
Directors' responsibilities statement
1
Balance sheet
2 - 3
Statement of changes in equity
4
Notes to the financial statements
5 - 9
RUBY PHARMACY LIMITED
DIRECTORS' RESPONSIBILITIES STATEMENT
FOR THE YEAR ENDED 31 OCTOBER 2025
- 1 -

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period.

In preparing these financial statements, the directors are required to:

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

RUBY PHARMACY LIMITED
BALANCE SHEET
AS AT 31 OCTOBER 2025
31 October 2025
- 2 -
2025
2024
Notes
£
£
£
£
Fixed assets
Intangible assets
3
617,516
671,213
Tangible assets
4
7,165
9,167
624,681
680,380
Current assets
Stocks
5
56,459
57,995
Debtors
6
286,681
231,569
Cash at bank and in hand
31,160
59,268
374,300
348,832
Creditors: amounts falling due within one year
7
(540,716)
(549,286)
Net current liabilities
(166,416)
(200,454)
Total assets less current liabilities
458,265
479,926
Creditors: amounts falling due after more than one year
8
(444,781)
(467,793)
Net assets
13,484
12,133
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
13,384
12,033
Total equity
13,484
12,133
RUBY PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT 31 OCTOBER 2025
31 October 2025
- 3 -

For the financial year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 29 July 2026 and are signed on its behalf by:
Miss Valerie Mackay
Mr Richard Smyth
Director
Director
Company registration number 13681455 (England and Wales)
RUBY PHARMACY LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 OCTOBER 2025
- 4 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 November 2023
100
20,245
20,345
Year ended 31 October 2024:
Profit and total comprehensive income
-
41,788
41,788
Dividends
-
(50,000)
(50,000)
Balance at 31 October 2024
100
12,033
12,133
Year ended 31 October 2025:
Profit and total comprehensive income
-
58,851
58,851
Dividends
-
(57,500)
(57,500)
Balance at 31 October 2025
100
13,384
13,484
RUBY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2025
- 5 -
1
Accounting policies
Company information

Ruby Pharmacy Limited is a private company limited by shares incorporated in England and Wales. The registered office is Suite 2d Building 1, Eastern Business Park, St Mellons, Cardiff, CF3 5EA.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

 

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Revenue from contracts for the provision of professional services is recognised by reference to the stage of completion when the stage of completion, costs incurred and costs to complete can be estimated reliably. The stage of completion is calculated by comparing costs incurred, mainly in relation to contractual hourly staff rates and materials, as a proportion of total costs. Where the outcome cannot be estimated reliably, revenue is recognised only to the extent of the expenses recognised that are recoverable.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 10 years.

 

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

RUBY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 6 -
1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
25% on a reducing balance basis
Computers
33% on a straight line basis
1.5
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.8
Leases
As lessee
RUBY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
1
Accounting policies
(Continued)
- 7 -

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
10
7
3
Intangible fixed assets
Goodwill
£
Cost
At 1 November 2024 and 31 October 2025
805,456
Amortisation and impairment
At 1 November 2024
134,243
Amortisation charged for the year
53,697
At 31 October 2025
187,940
Carrying amount
At 31 October 2025
617,516
At 31 October 2024
671,213
4
Tangible fixed assets
Fixtures and fittings
Computers
Total
£
£
£
Cost
At 1 November 2024
13,819
2,993
16,812
Additions
-
0
917
917
At 31 October 2025
13,819
3,910
17,729
Depreciation and impairment
At 1 November 2024
6,502
1,145
7,647
Depreciation charged in the year
1,829
1,088
2,917
At 31 October 2025
8,331
2,233
10,564
RUBY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
4
Tangible fixed assets
Fixtures and fittings
Computers
Total
£
£
£
(Continued)
- 8 -
Carrying amount
At 31 October 2025
5,488
1,677
7,165
At 31 October 2024
7,318
1,849
9,167
5
Stocks
2025
2024
£
£
Stocks
56,459
57,995
6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
241,865
205,930
Other debtors
44,470
25,400
286,335
231,330
Deferred tax asset (note )
346
239
286,681
231,569
7
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
68
68
Trade creditors
151,222
166,205
Corporation tax
54,404
37,820
Other taxation and social security
3,868
848
Other creditors
330,441
344,066
Accruals and deferred income
713
279
540,716
549,286
8
Creditors: amounts falling due after more than one year
2025
2024
Notes
£
£
Bank loans and overdrafts
444,781
467,793
RUBY PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2025
- 9 -
9
Related party transactions

As at the balance sheet date, the company owed the directors £221,525 (£245,270 - 2024)

10
Ultimate Controlling Party

The company's ultimate controlling party are Miss Valerie Mackay and Mr Richard Smyth by virtue of their ownership of 100% of the issued share capital in the company.

2025-10-312024-11-01falsefalsefalse29 July 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityMiss V MacKayRichard Smyth & Valerie Mackay136814552024-11-012025-10-31136814552025-10-31136814552024-10-3113681455core:Goodwill2025-10-3113681455core:Goodwill2024-10-3113681455core:FurnitureFittings2025-10-3113681455core:ComputerEquipment2025-10-3113681455core:FurnitureFittings2024-10-3113681455core:ComputerEquipment2024-10-3113681455core:CurrentInventories2025-10-3113681455core:CurrentInventories2024-10-3113681455core:WithinOneYear2025-10-3113681455core:WithinOneYear2024-10-3113681455core:AfterOneYear2025-10-3113681455core:AfterOneYear2024-10-3113681455core:CurrentFinancialInstrumentscore:WithinOneYear2025-10-3113681455core:CurrentFinancialInstrumentscore:WithinOneYear2024-10-3113681455core:ShareCapital2025-10-3113681455core:ShareCapital2024-10-3113681455core:RetainedEarningsAccumulatedLosses2025-10-3113681455core:RetainedEarningsAccumulatedLosses2024-10-3113681455core:ShareCapital2023-10-3113681455core:RetainedEarningsAccumulatedLosses2023-10-3113681455bus:Director12024-11-012025-10-3113681455bus:Director22024-11-012025-10-3113681455core:RetainedEarningsAccumulatedLosses2023-11-012024-10-31136814552023-11-012024-10-3113681455core:RetainedEarningsAccumulatedLosses2024-11-012025-10-3113681455core:Goodwill2024-11-012025-10-3113681455core:FurnitureFittings2024-11-012025-10-3113681455core:ComputerEquipment2024-11-012025-10-3113681455core:Goodwill2024-10-3113681455core:FurnitureFittings2024-10-3113681455core:ComputerEquipment2024-10-31136814552024-10-3113681455core:CurrentFinancialInstruments2025-10-3113681455core:CurrentFinancialInstruments2024-10-3113681455core:Non-currentFinancialInstruments2025-10-3113681455core:Non-currentFinancialInstruments2024-10-3113681455bus:PrivateLimitedCompanyLtd2024-11-012025-10-3113681455bus:SmallCompaniesRegimeForAccounts2024-11-012025-10-3113681455bus:FRS1022024-11-012025-10-3113681455bus:AuditExemptWithAccountantsReport2024-11-012025-10-3113681455bus:FullAccounts2024-11-012025-10-31xbrli:purexbrli:sharesiso4217:GBP